RED TERAV - Investigadores

Investigadores

Instituto de Investigación Universitario Valle de Hebron (VHIR). Barcelona.

Inmunoterapia Celular (células CAR)

Investigadores
Publicaciones

Francesc Bosch Albareda

Investigador principal

Grupo de Investigación: Instituto de Investigación Universitario Valle de Hebron (VHIR). Barcelona.

Jordi BARQUINERO MÁÑEZ

Investigador principal

Grupo de Investigación: Instituto de Investigación Universitario Valle de Hebron (VHIR). Barcelona.

Maria Pallarès Masmitjà

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Universitario Valle de Hebron (VHIR). Barcelona.

PERE BARBA SUÑOL

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Universitario Valle de Hebron (VHIR). Barcelona.

ROCIO PIÑERA MORENO

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Universitario Valle de Hebron (VHIR). Barcelona.

Serna Á., Navarro V., Iacoboni G., López L., Sancho J.M., González-Barca E., López-García A., Córdoba R., Sáez A., Jiménez-Ubieto A., Ferrero A., García T., Sánchez Á., García C., Bosch M., Cabirta A., Jiménez M., Marín-Niebla A., Bosch F., Abrisqueta P.. Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes. Haematologica. January 2025. DOI: 10.3324/haematol.2024.285219.

Impacto: 8.2. Cuartil: Q1

Hidalgo-Gómez G., Tazón-Vega B., Palacio C., Saumell S., Martínez-Morgado N., Navarro V., Murillo L., Velasco P., Murciano T., Díaz de Heredia C., Bosch F., Armengol G., Ortega M.. How to combine multiple tools for the genetic diagnosis work-up of pediatric B-cell acute lymphoblastic leukemia. Annals of Hematology. 2025. DOI: 10.1007/s00277-024-06151-7.

Impacto: 3.0. Cuartil: Q2

Medina Á., Muntañola A., Crespo M., Ramírez Á., Hernández-Rivas J.Á., Abrisqueta P., Alcoceba M., Delgado J., de la Serna J., Espinet B., González M., Loscertales J., Serrano A., Terol M.J., Yáñez L., Bosch F.. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC). Medicina Clinica. 2025. DOI: 10.1016/j.medcli.2024.10.018.

Impacto: 2.6. Cuartil: Q1

Río P., Zubicaray J., Navarro S., Gálvez E., Sánchez-Domínguez R., Nicoletti E., Sebastián E., Rothe M., Pujol R., Bogliolo M., John-Neek P., Bastone A.L., Schambach A., Wang W., Schmidt M., Larcher L., Segovia J.C., Yáñez R.M., Alberquilla O., Díez B., Fernández-García M., García-García L., Ramírez M., Galy A., Lefrere F., Cavazzana M., Leblanc T., García de Andoin N., López-Almaraz R., Catalá A., Barquinero J., Rodríguez-Perales S., Rao G., Surrallés J., Soulier J., Díaz-de-Heredia C., Schwartz J.D., Sevilla J., Bueren J.A.. Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials. The Lancet. 21 December 2024. DOI: 10.1016/S0140-6736(24)01880-4.

Impacto: 98.4. Cuartil: Q1 (1er decil)

Iacoboni G., Navarro V., Sesques P., Rejeski K., Bastos-Oreiro M., Serpenti F., Martin Lopez A.A., Iraola-Truchuelo J., Delgado J., Perez A., Guerreiro M., Caballero A.C., Martinez-Cibrian N., Luzardo Henriquez H., Sanchez Pina J.M., Sancho J.M., Ghesquieres H., Mussetti A., Lopez Corral L., Hernani R., Reguera J.L., Sureda A., Bosch F., Martin Garcia-Sancho A., Kwon M., Subklewe M., Kuhnl A., Bachy E., Barba P., Villacampa G., Abrisqueta P.. Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment. Journal of Hematology and Oncology. December 2024. DOI: 10.1186/s13045-024-01608-8.

Impacto: 29.5. Cuartil: Q1 (1er decil)

Montoro M.J., Palomo L., Haferlach C., Acha P., Chan O., Navarro V., Kubota Y., Schulz F.I., Meggendorfer M., Briski R., Al Ali N., Xicoy B., López-Cadenas F., Bosch F., González T., Eder L.N., Jerez A., Wang Y.H., Campagna A., Santini V., Bernal del Castillo T., Such E., Tien H.F., Diaz Varela N., Platzbecker U., Haase D., Díez-Campelo M., Della Porta M., Garcia-Manero G., Wiseman D.H., Germing U., Maciejewski J.P., Komrokji R.S., Sole F., Haferlach T., Valcárcel D.. Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion. Blood. 17 October 2024. DOI: 10.1182/blood.2024023840.

Impacto: 21.0. Cuartil: Q1 (1er decil)

Fox M.L., García-Cadenas I., Navarro V., Martínez A.P., Kara M., Bazán I.S., Ferra Coll C., Bailén R., Bento L., Parody R., Esquirol A., Ortí G., Mussetti A., Salamero O., Martino R., González A.P., Barba P., Kwon M., Solano C., Bosch F., Valcárcel D.. Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies. Bone Marrow Transplantation. October 2024. DOI: 10.1038/s41409-024-02322-2.

Impacto: 4.5. Cuartil: Q1

Chatzikonstantinou T., Scarfò L., Minga E., Karakatsoulis G., Chamou D., Kotaskova J., Iacoboni G., Demosthenous C., Albi E., Alcoceba M., Al-Shemari S., Aurran-Schleinitz T., Bacchiarri F., Chatzileontiadou S., Collado R., Davis Z., de Deus Santos M.D., Dimou M., Dmitrieva E., Donaldson D., Dos Santos G., Dreta B., Efstathopoulou M., El-Ashwah S., Enrico A., Frygier A., Galimberti S., Galitzia A., Gimeno E., Guarente V., Guieze R., Harrop S., Hatzimichael E., Herishanu Y., Hernández-Rivas J.Á., Jaksic O., Kalicińska E., Laribi K., Karakus V., Kater A.P., Kho B., Kislova M., Konstantinou Ε., Koren-Michowitz M., Kotsianidis I., Kubova Z., Labrador J., Lad D., Laurenti L., Longval T., Lopez-Garcia A., Marquet J., Maslejova S., Mayor-Bastida C., Mihaljevic B., Milosevic I., Miras F., Moia R., Morawska M., Nath U.K., Navarro-Bailón A., Olivieri J., Panovska-Stavridis I., Papaioannou M., Pierie C., Puiggros A., Reda G., Rigolin G.M., Ruchlemer R., Schipani M., Schiwitza A., Shen Y., Shokralla T., Simkovic M., Smirnova S., Soliman D.S.A., Stilgenbauer S., Tadmor T., Tomic K., Tse E., Vassilakopoulos T., Visentin A., Vitale C., Vrachiolias G., Vukovic V., Walewska R., Xu Z., Yagci M., Yañez L., Yassin M., Zuchnicka J., Oscier D., Gozzetti A., Panagiotidis P., Bosch F., Sportoletti P., Espinet B., Pangalis G.A., Popov V.M., Mulligan S.. Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL. HemaSphere. September 2024. DOI: 10.1002/hem3.70004.

Impacto: 7.6. Cuartil: Q1

Torres-Esquius S., Beas F., Chen-Liang T.H., Pomares H., Santiago M., Varela N.D., Liquori A., Hernandez F., Xicoy B., Hermosín L., Arnan M., Tazón-Vega B., Blanco A., Cervera J., Diez-Campelo M., Lozano M.L., Valcárcel D., Bosch F., Montoro M.J., Jerez A.. Germline assessment for alloHSCT candidates over 50 years: A ‘Fast-Track’ screening in myeloid neoplasms. British Journal of Haematology. August 2024. DOI: 10.1111/bjh.19460.

Impacto: 5.1. Cuartil: Q1

Crochet G., Iacoboni G., Couturier A., Bachy E., Iraola-Truchuelo J., Gastinne T., Cartron G., Fradon T., Lesne B., Kwon M., Gounot R., Martínez-Cibrian N., Castilla-Llorente C., Abrisqueta P., Guerreiro M., Sarkozy C., Aspa-Cilleruelo J.M., Camus V., Guidez S., Chauchet A., Deconinck E., Bouabdallah K., Bosch F., Barba P., Morschhauser F., Houot R.. Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma. Blood. 18 July 2024. DOI: 10.1182/blood.2024024526.

Impacto: 21.0. Cuartil: Q1 (1er decil)

Salamero O., Molero A., Pérez-Simón J.A., Arnan M., Coll R., Garcia-Avila S., Acuña-Cruz E., Cano I., Somervaille T.C.P., Gutierrez S., Arévalo M.I., Xaus J., Buesa C., Limón A., Faller D.V., Bosch F., Montesinos P.. Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study. The Lancet Haematology. July 2024. DOI: 10.1016/S2352-3026(24)00132-7.

Impacto: 15.4. Cuartil: Q1 (1er decil)

Abrisqueta P., González-Barca E., Ferrà C., Ríos-Herranz E., Fernández de la Mata M., Delgado J., Andreu R., Hernández-Rivas J.Á., Terol M.J., Navarro A., Vidriales M.B., Baltasar P., De la Serna J., Ramírez Á., Ballester C., Moreno C., García-Marco J.A., Córdoba R., Yáñez L., Casado L.F., González M., Bosch F.. Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC). eClinicalMedicine. July 2024. DOI: 10.1016/j.eclinm.2024.102642.

Impacto: 9.6. Cuartil: Q1 (1er decil)

Budde L.E., Assouline S., Sehn L.H., Schuster S.J., Yoon S.S., Yoon D.H., Matasar M.J., Bosch F., Kim W.S., Nastoupil L.J., Flinn I.W., Shadman M., Diefenbach C., Cheah C.Y., Ma C.Y., Huang H., Kwan A., Wei M.C., Yin S., Bartlett N.L.. Durable Responses with Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of Clinical Oncology. 1 July 2024. DOI: 10.1200/JCO.23.02329.

Impacto: 42.1. Cuartil: Q1 (1er decil)

Smeets H., Verbrugge B., Bulbena X., Hristova L., Vogt J., van Beckhoven I., Allamand V., Almekinders J., Barquinero J., Berreur S., Bönnemann C., Bouman K., de Bruin L., Caron L., Damon C., Durbeej M., Feijen D., Foley R., Goncalves A.R., Camelo C.G., Güell M., Haliloğlu G., Kemaladewi D., Klein A., Koleda N., Minko O., Munell F., Nebermann T., Pini V., Previtali S., Roos A., Rüegg M., Sarkozy A., Seferian A., Stepniewski J., van Straten E., van Tienen F., Quijano-Roy S., Voermans N., West A., Yurchenco P., Moy J., Almeida C., Becker J., Gill L.. European Joint Programme on Rare Diseases workshop: LAMA2-muscular dystrophy: paving the road to therapy March 17–19, 2023, Barcelona, Spain. Neuromuscular Disorders. March 2024. DOI: 10.1016/j.nmd.2024.01.001.

Impacto: 2.7. Cuartil: Q2

Bosch F., Kuruvilla J., Vassilakopoulos T.P., Maio D.D., Wei M.C., Zumofen M.H.B., Nastoupil L.J.. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. Clinical Lymphoma, Myeloma and Leukemia. February 2024. DOI: 10.1016/j.clml.2023.09.007.

Impacto: 2.7. Cuartil: Q2

Chatzikonstantinou T., Scarfò L., Karakatsoulis G., Minga E., Chamou D., Iacoboni G., Kotaskova J., Demosthenous C., Smolej L., Mulligan S., Alcoceba M., Al-Shemari S., Aurran-Schleinitz T., Bacchiarri F., Bellido M., Bijou F., Calleja A., Medina A., Khan M.A., Cassin R., Chatzileontiadou S., Collado R., Christian A., Davis Z., Dimou M., Donaldson D., Santos G.D., Dreta B., Efstathopoulou M., El-Ashwah S., Enrico A., Fresa A., Galimberti S., Galitzia A., García-Serra R., Gimeno E., González-Gascón-y-Marín I., Gozzetti A., Guarente V., Guieze R., Gogia A., Gupta R., Harrop S., Hatzimichael E., Herishanu Y., Hernández-Rivas J.Á., Inchiappa L., Jaksic O., Janssen S., Kalicińska E., Kamel L., Karakus V., Kater A.P., Kho B., Kislova M., Konstantinou E., Koren-Michowitz M., Kotsianidis I., Kreitman R.J., Labrador J., Lad D., Levin M.D., Levy I., Longval T., Lopez-Garcia A., Marquet J., Martin-Rodríguez L., Maynadié M., Maslejova S., Mayor-Bastida C., Mihaljevic B., Milosevic I., Miras F., Moia R., Morawska M., Murru R., Nath U.K., Navarro-Bailón A., Oliveira A.C., Olivieri J., Oscier D., Panovska-Stavridis I., Papaioannou M., Papajík T., Kubova Z., Phumphukhieo P., Pierie C., Puiggros A., Rani L., Reda G., Rigolin G.M., Ruchlemer R., Daniel de Deus Santos M., Schipani M., Schiwitza A., Shen Y., Simkovic M., Smirnova S., Abdelrahman Soliman D.S., Spacek M.. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. eClinicalMedicine. November 2023. DOI: 10.1016/j.eclinm.2023.102307.

Impacto: 9.6. Cuartil: Q1 (1er decil)

Abrisqueta P., Nadeu F., Bosch-Schips J., Iacoboni G., Serna A., Cabirta A., Yáñez L., Quintanilla-Martínez L., Bosch F.. From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia. Cancer Treatment Reviews. November 2023. DOI: 10.1016/j.ctrv.2023.102619.

Impacto: 9.6. Cuartil: Q1

Bartlett N.L., Assouline S., Giri P., Schuster S.J., Cheah C.Y., Matasar M., Gregory G.P., Yoon D.H., Shadman M., Fay K., Yoon S.S., Panizo C., Flinn I., Johnston A., Bosch F., Sehn L.H., Wei M.C., Yin S., To I., Li C.C., Huang H., Kwan A., Penuel E., Budde L.E.. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Advances. 12 September 2023. DOI: 10.1182/bloodadvances.2022009260.

Impacto: 7.4. Cuartil: Q1

Jiménez M., Fernández-Naval C., Navarro V., Novoa S., Martinez-Gallo M., Medina D., Andrés C., Antón A., Peralta S., Pujadas G., Hernández C., Pagès C., Roldán E., Pumarola T., Gironella M., Ruiz-Camps I., Martínez-Gómez X., Valcárcel D., Hernández M., Bosch F., Crespo M., Esperalba J., Abrisqueta P.. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms. American Journal of Hematology. August 2023. DOI: 10.1002/ajh.26951.

Impacto: 10.1. Cuartil: Q1 (1er decil)

Mansouri L., Thorvaldsdottir B., Sutton L.A., Karakatsoulis G., Meggendorfer M., Parker H., Nadeu F., Brieghel C., Laidou S., Moia R., Rossi D., Catherwood M., Kotaskova J., Delgado J., Rodríguez-Vicente A.E., Benito R., Rigolin G.M., Bonfiglio S., Scarfo L., Mattsson M., Davis Z., Gogia A., Rani L., Baliakas P., Foroughi-Asl H., Jylhä C., Skaftason A., Rapado I., Miras F., Martinez-Lopez J., de la Serna J., Rivas J.M.H., Thornton P., Larráyoz M.J., Calasanz M.J., Fésüs V., Mátrai Z., Bödör C., Smedby K.E., Espinet B., Puiggros A., Gupta R., Bullinger L., Bosch F., Tazón-Vega B., Baran-Marszak F., Oscier D., Nguyen-Khac F., Zenz T., Terol M.J., Cuneo A., Hernández-Sánchez M., Pospisilova S., Mills K., Gaidano G., Niemann C.U., Campo E., Strefford J.C., Ghia P., Stamatopoulos K., Rosenquist R.. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Leukemia. February 2023. DOI: 10.1038/s41375-022-01802-y.

Impacto: 12.8. Cuartil: Q1 (1er decil)

Mansouri L., Thorvaldsdottir B., Sutton L.A., Karakatsoulis G., Meggendorfer M., Parker H., Nadeu F., Brieghel C., Laidou S., Moia R., Rossi D., Catherwood M., Kotaskova J., Delgado J., Rodríguez-Vicente A.E., Benito R., Rigolin G.M., Bonfiglio S., Scarfo L., Mattsson M., Davis Z., Gogia A., Rani L., Baliakas P., Foroughi-Asl H., Jylhä C., Skaftason A., Rapado I., Miras F., Martinez-Lopez J., de la Serna J., Rivas J.M.H., Thornton P., Larráyoz M.J., Calasanz M.J., Fésüs V., Mátrai Z., Bödör C., Smedby K.E., Espinet B., Puiggros A., Gupta R., Bullinger L., Bosch F., Tazón-Vega B., Baran-Marszak F., Oscier D., Nguyen-Khac F., Zenz T., Terol M.J., Cuneo A., Hernández-Sánchez M., Pospisilova S., Mills K., Gaidano G., Niemann C.U., Campo E., Strefford J.C., Ghia P., Stamatopoulos K., Rosenquist R.. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y). Leukemia. February 2023. DOI: 10.1038/s41375-023-01813-3.

Impacto: 12.8. Cuartil: Q1 (1er decil)

Ribeiro M.L., Profitós-Pelejà N., Santos J.C., Blecua P., Reyes-Garau D., Armengol M., Fernández-Serrano M., Miskin H.P., Bosch F., Esteller M., Normant E., Roué G.. G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy. Frontiers in Immunology. 2023. DOI: 10.3389/fimmu.2023.1130052.

Impacto: 5.7. Cuartil: Q1

Gordon L.I., Karmali R., Kaplan J.B., Popat R., Burris H.A., Ferrari S., Madan S., Patel M.R., Gritti G., El-Sharkawi D., Chau F.I., Radford J., de Oteyza J.P., Zinzani P.L., Iyer S.P., Townsend W., Miao H., Proscurshim I., Wang S., Katyayan S., Yuan Y., Zhu J., Stumpo K., Shou Y., Carpio C., Bosch F.. Spleen tyrosine kinase/FMS-Like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/ CB-659. Oncotarget. 2023. DOI: 10.18632/oncotarget.28352.

Cuenca S., Soler Z., Serrano-Gómez G., Xie Z., Barquinero J., Roca J., Sirvent J.M., Manichanh C.. Dysbiosis: An Indicator of COVID-19 Severity in Critically Ill Patients. International Journal of Molecular Sciences. December 2022. DOI: 10.3390/ijms232415808.

Impacto: 5.6. Cuartil: Q1

Dlouhy I., Armengol M., Recasens-Zorzo C., Ribeiro M.L., Pérez-Galán P., Bosch F., López-Guillermo A., Roué G.. Erratum: Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-kB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation (Haematologica (2021) 106:10 (2749-2753) DOI: 10.3324/haema-tol.2020.278258). Haematologica. December 2022. DOI: 10.3324/haematol.2022.281988.

Impacto: 10.1. Cuartil: Q1 (1er decil)

Abrisqueta P., Medina D., Villacampa G., Lu J., Alcoceba M., Carabia J., Boix J., Tazón-Vega B., Iacoboni G., Bobillo S., Marín-Niebla A., González M., Zenz T., Crespo M., Bosch F.. A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. Blood Advances. 8 November 2022. DOI: 10.1182/bloodadvances.2022007508.

Impacto: 7.5. Cuartil: Q1

Galiñanes M., Casós K., Blasco-Lucas A., Permanyer E., Máñez R., Le Tourneau T., Barquinero J., Schwartz S., Bottio T., Roussel J.C., Fellah-Hebia I., Sénage T., Evangelista A., Badano L.P., Ruiz-Majoral A., Galli C., Padler-Karavani V., Soulillou J.P., Vidal X., Cozzi E., Costa C.. Oxidative Stress in Structural Valve Deterioration: A Longitudinal Clinical Study. Biomolecules. November 2022. DOI: 10.3390/biom12111606.

Impacto: 5.5. Cuartil: Q1

Jiménez M., Bobillo S., Pons V., Sánchez C., Pérez A., Molero A., Miranda N., Sánchez Á., Tabares E., Bosch F., Valcárcel D.. Real-world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura: A single-center with homogeneous treatment experience. Transfusion. November 2022. DOI: 10.1111/trf.17111.

Impacto: 2.9. Cuartil: Q3

Nadeu F., Royo R., Massoni-Badosa R., Playa-Albinyana H., Garcia-Torre B., Duran-Ferrer M., Dawson K.J., Kulis M., Diaz-Navarro A., Villamor N., Melero J.L., Chapaprieta V., Dueso-Barroso A., Delgado J., Moia R., Ruiz-Gil S., Marchese D., Giró A., Verdaguer-Dot N., Romo M., Clot G., Rozman M., Frigola G., Rivas-Delgado A., Baumann T., Alcoceba M., González M., Climent F., Abrisqueta P., Castellví J., Bosch F., Aymerich M., Enjuanes A., Ruiz-Gaspà S., López-Guillermo A., Jares P., Beà S., Capella-Gutierrez S., Gelpí J.L., López-Bigas N., Torrents D., Campbell P.J., Gut I., Rossi D., Gaidano G., Puente X.S., Garcia-Roves P.M., Colomer D., Heyn H., Maura F., Martín-Subero J.I., Campo E.. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia. Nature Medicine. August 2022. DOI: 10.1038/s41591-022-01927-8.

Impacto: 82.9. Cuartil: Q1 (1er decil)

Catalá E., Iacoboni G., Vidal-Jordana Á., Oristrell G., Carpio C., Vilaseca A., Cabirta A., Bosch F., Tintoré M., Barba P.. Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy. Hematological Oncology. August 2022. DOI: 10.1002/hon.2976.

Impacto: 3.3. Cuartil: Q2

Ramos-Campoy S., Puiggros A., Beà S., Bougeon S., Larráyoz M.J., Costa D., Parker H., Rigolin G.M., Ortega M., Blanco M.L., Collado R., Salgado R., Baumann T., Gimeno E., Moreno C., Bosch F., Calvo X., Calasanz M.J., Cuneo A., Strefford J.C., Nguyen-Khac F., Oscier D., Haferlach C., Schoumans J., Espinet B.. Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. Haematologica. March 2022. DOI: 10.3324/haematol.2020.274456.

Impacto: 10.1. Cuartil: Q1 (1er decil)

Budde L.E., Assouline S., Sehn L.H., Schuster S.J., Yoon S.S., Yoon D.H., Matasar M.J., Bosch F., Kim W.S., Nastoupil L.J., Flinn I.W., Shadman M., Diefenbach C., O'Hear C., Huang H., Kwan A., Li C.C., Piccione E.C., Wei M.C., Yin S., Bartlett N.L.. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients with Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of Clinical Oncology. 10 February 2022. DOI: 10.1200/JCO.21.00931.

Impacto: 45.3. Cuartil: Q1 (1er decil)

Jimenez M., Roldan E., Fernandez-Naval C., Villacampa G., Martinez-Gallo M., Medina-Gil D., Peralta-Garzon S., Pujadas G., Hernandez C., Pages C., Gironella M., Fox L., Orti G., Barba P., Pumarola T., Cabirta A., Catala E., Valentın M., Marın-Niebla A., Orfao A., Gonzalez M., Campins M., Ruiz-Camps I., Valcarcel D., Bosch F., Hernandez M., Crespo M., Esperalba J., Abrisqueta P.. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Advances. 8 February 2022. DOI: 10.1182/bloodadvances.2021006101.

Impacto: 7.5. Cuartil: Q1

Quinet G., Xolalpa W., Reyes-Garau D., Profitós-Pelejà N., Azkargorta M., Ceccato L., Gonzalez-Santamarta M., Marsal M., Andilla J., Aillet F., Bosch F., Elortza F., Loza-Alvarez P., Sola B., Coux O., Matthiesen R., Roué G., Rodriguez M.S.. Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma. Cancers. February-2 2022. DOI: 10.3390/cancers14040923.

Impacto: 5.2. Cuartil: Q2

Cabirta A., Hidalgo-Gómez G., Marín-Niebla A., Gallur L., Saumell S., Castellví J., Catalá E., Blanco A., López-Andreoni L., Montoro M.J., Navarrete M., Palacio-García C., Tazón-Vega B., Bobillo S., Bosch F., Ortega M.. Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma. Leukemia and Lymphoma. 2022. DOI: 10.1080/10428194.2022.2034158.

Impacto: 2.6. Cuartil: Q3

Piñana J.L., Vázquez L., Martino R., de la Cámara R., Sureda A., Rodríguez-Veiga R., Garrido A., Sierra J., Ribera J.M., Torrent A., Mateos M.V., de la Rubia J., Tormo M., Díez-Campelo M., García-Gutiérrez V., Álvarez-Larrán A., Sancho J.M., MartínGarcía-Sancho A., Yañez L., Pérez Simón J.A., Barba P., Abrisqueta P., Álvarez-Twose I., Bonanad S., Lecumberri R., Ruiz-Camps I., Navarro D., Hernández-Rivas J.Á., Cedillo Á., García-Sanz R., Bosch F.. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Leukemia and Lymphoma. 2022. DOI: 10.1080/10428194.2021.1992619.

Impacto: 2.6. Cuartil: Q3

Jiménez I., Tazón-Vega B., Abrisqueta P., Nieto J.C., Bobillo S., Palacio-García C., Carabia J., Valdés-Mas R., Munuera M., Puigdefàbregas L., Parra G., Esteve-Codina A., Franco-Jarava C., Iacoboni G., Terol M.J., García-Marco J.A., Crespo M., Bosch F.. Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. Biomarker Research. December 2021. DOI: 10.1186/s40364-021-00290-z.

Impacto: 8.633. Cuartil: Q1

Pallarès-Masmitjà M., Ivančić D., Mir-Pedrol J., Jaraba-Wallace J., Tagliani T., Oliva B., Rahmeh A., Sánchez-Mejías A., Güell M.. Find and cut-and-transfer (FiCAT) mammalian genome engineering. Nature Communications. December 2021. DOI: 10.1038/s41467-021-27183-x.

Impacto: 17.694. Cuartil: Q1 (1er decil)

Ribeiro M.L., Reyes-Garau D., Vinyoles M., Pelejà N.P., Santos J.C., Armengol M., Fernández-Serrano M., Mor A.S., Bech-Serra J.J., Blecua P., Musulen E., de la Torre C., Miskin H., Esteller M., Bosch F., Menéndez P., Normant E., Roué G.. Antitumor activity of the novel BTK inhibitor TG-1701 is associated with disruption of ikaros signaling in patients with B-cell non–hodgkin lymphoma. Clinical Cancer Research. 1 December 2021. DOI: 10.1158/1078-0432.CCR-21-1067.

Impacto: 13.801. Cuartil: Q1 (1er decil)

Villacampa G., Dienstmann R., Bosch F., Abrisqueta P.. Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.. Annals of Hematology. December 2021. DOI: 10.1007/s00277-021-04623-8.

Impacto: 4.03. Cuartil: Q2

Dlouhy I., Armengol M., Recasens-Zorzo C., Ribeiro M.L., Pérez-Galán P., Bosch F., López-Guillermo A., Roué G.. Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation. Haematologica. October 2021. DOI: 10.3324/haematol.2020.278258.

Impacto: 11.047. Cuartil: Q1 (1er decil)

Puiggros A., Blanco G., Muntasell A., Rodríguez-Rivera M., Nonell L., Altadill M., Puigdecanet E., Arnal M., Calvo X., Gimeno E., Abella E., Abrisqueta P., Bosch F., Yélamos J., Ferrer A., López-Botet M., Espinet B.. Reduced expansion of CD94/NKG2C<sup>+</sup> NK cells in chronic lymphocytic leukemia and CLL-like monoclonal B-cell lymphocytosis is not related to increased human cytomegalovirus seronegativity or NKG2C deletions. International Journal of Laboratory Hematology. October 2021. DOI: 10.1111/ijlh.13494.

Impacto: 3.45. Cuartil: Q3

Parés M., Fornaguera C., Vila-Julià F., Oh S., Fan S.H.Y., Tam Y.K., Comes N., Vidal F., Martí R., Borrós S., Barquinero J.. Preclinical Assessment of a Gene-Editing Approach in a Mouse Model of Mitochondrial Neurogastrointestinal Encephalomyopathy. Human Gene Therapy. October 2021. DOI: 10.1089/hum.2021.152.

Impacto: 4.793. Cuartil: Q1

Iacoboni G., Simó M., Villacampa G., Catalá E., Carpio C., Díaz-Lagares C., Vidal-Jordana Á., Bobillo S., Marín-Niebla A., Pérez A., Jiménez M., Abrisqueta P., Bosch F., Barba P.. Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. Annals of Hematology. September 2021. DOI: 10.1007/s00277-021-04560-6.

Impacto: 4.03. Cuartil: Q2

Bosch F., Dalla-Favera R.. Genetics of Chronic Lymphocytic Leukemia. Cancer Journal (United States). 2021. DOI: 10.1097/PPO.0000000000000538.

Impacto: 2.074. Cuartil: Q4

Stilgenbauer S., Bosch F., Ilhan O., Kisro J., Mahé B., Mikuskova E., Osmanov D., Reda G., Robinson S., Tausch E., Turgut M., Wójtowicz M., Böttcher S., Perretti T., Trask P., Van Hoef M., Leblond V., Foà R.. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. British Journal of Haematology. April 2021. DOI: 10.1111/bjh.17326.

Impacto: 8.615. Cuartil: Q1

Blanco G., Puiggros A., Sherry B., Nonell L., Calvo X., Puigdecanet E., Chiu P.Y., Kieso Y., Ferrer G., Palacios F., Arnal M., Rodríguez-Rivera M., Gimeno E., Abella E., Rai K.R., Abrisqueta P., Bosch F., Calon A., Ferrer A., Chiorazzi N., Espinet B.. Chronic lymphocytic leukemia–like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia. Experimental Hematology. March 2021. DOI: 10.1016/j.exphem.2020.12.007.

Impacto: 3.249. Cuartil: Q3

Bosch F., Navarro B., Crespo M., Alcoceba M., Sánchez J.B., Tazón B., Serrano A., Álvarez M.G., Serrano L.G., Alonso-Torres P., Villanueva M., Loriente C., Abrisqueta P., Peiró M., García-Marco J.A., González M., Terol M.J.. Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. Annals of Hematology. March 2021. DOI: 10.1007/s00277-020-04331-9.

Impacto: 4.03. Cuartil: Q2

Bobillo S., Crespo M., Escudero L., Mayor R., Raheja P., Carpio C., Rubio-Perez C., Tazón-Vega B., Palacio C., Carabia J., Jiménez I., Juan C.N., Montoro J., Martínez-Ricarte F., Castellví J., Simó M., Puigdefàbregas L., Abrisqueta P., Bosch F., Seoane J.. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. February 2021. DOI: 10.3324/haematol.2019.241208.

Impacto: 11.047. Cuartil: Q1 (1er decil)

Carpio C., Iacoboni G., Villacampa G., Catalá E., Bobillo S., Pérez A., Jiménez M., Segura L., Olivé M., Farriols A., Abrisqueta P., Valcárcel D., Carreras M.J., Bosch F., Barba P.. Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center. Leukemia and Lymphoma. 2021. DOI: 10.1080/10428194.2021.1913141.

Impacto: 2.996. Cuartil: Q3

Hidalgo-Gómez G., Palacio-Garcia C., Gallur L., Blanco A., Tazón-Vega B., Saumell S., Martínez N., Murillo L., Murciano T., Velasco P., Bosch F., Diaz-Heredia C., Ortega M.. Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis. Leukemia and Lymphoma. 2021. DOI: 10.1080/10428194.2021.1907375.

Impacto: 2.996. Cuartil: Q3

Ortí G., Palacio-Garcia C., García-Cadenas I., Sánchez-Ortega I., Jimenez M.J., Azqueta C., Villacampa G., Ferrà C., Parody R., Martino R., Bosch F., Querol S., Valcárcel D.. Analysis of Cell Subsets in Donor Lymphocyte Infusions from HLA Identical Sibling Donors after Allogeneic Hematopoietic Cell Transplant. Transplantation and Cellular Therapy. January 2021. DOI: 10.1016/j.bbmt.2020.09.024.

Impacto: 0.0. Cuartil: N/D

Salamero O., Montesinos P., Willekens C., Pérez-Simón J.A., Pigneux A., Récher C., Popat R., Carpio C., Molinero C., Mascaró C., Vila J., Isabel Arévalo M., Maes T., Buesa C., Bosch F., Somervaille T.C.P.. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology. 20 December 2020. DOI: 10.1200/JCO.19.03250.

Impacto: 44.544. Cuartil: Q1 (1er decil)

Muntañola A., Villacampa G., Hernández-Rivas J.Á., Alonso R., Mirás F., Osorio S., Baile M., Baltasar P., López Jiménez J., Hernandez-Rodriguez I., Valenciano S., Alfayate A., Gimeno E., Bárez A., Oliveira A.C., Riaza R., Romero P., Delgado J., Yáñez L., Zabalza A., Torres A., Gómez-Roncero M.ª., Crespo M., Córdoba R., Mateos-Mazón J.J., Pérez S., Andreu R., Labrador J., Ruiz M.ª., Velasquez C.A., Terol M.ª., Santiago R., Vidal M.ª., Campoy García F., Villalón L., Muiña B.S., Soler J.A., Seri C., Sánchez M.ª., Cuesta A., Ramos R., Sánchez-Montalvá A., Ruiz-Camps I., González M., Abrisqueta P., Bosch F.. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country. Experimental Hematology and Oncology. December 2020. DOI: 10.1186/s40164-020-00195-x.

Nieto J.C., Roldán E., Jiménez I., Fox L., Carabia J., Ortí G., Puigdefàbregas L., Gallur L., Iacoboni G., Raheja P., Pérez A., Bobillo S., Salamero O., Palacio C., Valcárcel D., Crespo M., Bosch F., Barba P.. Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy. Leukemia. December 2020. DOI: 10.1038/s41375-020-0851-8.

Impacto: 11.528. Cuartil: Q1 (1er decil)

Riveiro-Barciela M., Gubern P., Roade L., Abrisqueta P., Carreras M.J., Farriols A., Bosch F., Esteban R., Buti M.. An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders. Scientific Reports. 1 December 2020. DOI: 10.1038/s41598-020-59476-4.

Impacto: 4.379. Cuartil: Q1

Abrisqueta P., Delgado J., Alcoceba M., Oliveira A.C., Loscertales J., Hernández-Rivas J.A., Ferrà C., Cordoba R., Yáñez L., Medina A., Motlló C., Iacoboni G., Villacampa G., González M., Bosch F.. Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). British Journal of Haematology. 1 September 2020. DOI: 10.1111/bjh.16748.

Impacto: 6.998. Cuartil: Q1

Jiménez I., Carabia J., Bobillo S., Palacio C., Abrisqueta P., Pagès C., Nieto J.C., Castellví J., Martínez-Ricarte F., Escoda L., Perla C., Céspedes Torrez D.H., Boix J., Purroy N., Puigdefàbregas L., Seoane J., Bosch F., Crespo M.. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition. Journal of Neuro-Oncology. 1 August 2020. DOI: 10.1007/s11060-020-03580-y.

Impacto: 4.13. Cuartil: Q2

González-Gascón-y-Marín I., Muñoz-Novas C., Figueroa I., Hernández-Sánchez M., Rodríguez-Vicente A.E., Quijada-Álamo M., Pérez-Carretero C., Moreno C., Collado R., Espinet B., Puiggros A., Heras N.d.l., Bosch F., Hernández J.Á.. Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?. Clinical Lymphoma, Myeloma and Leukemia. August 2020. DOI: 10.1016/j.clml.2020.03.003.

Impacto: 3.231. Cuartil: Q3

Gordon L.I., Kaplan J.B., Popat R., Burris H.A., Ferrari S., Madan S., Patel M.R., Gritti G., El-Sharkawi D., Chau I., Radford J.A., de Oteyza J.P., Zinzani P.L., Iyer S., Townsend W., Karmali R., Miao H., Proscurshim I., Wang S., Wu Y., Stumpo K., Shou Y., Carpio C., Bosch F.. Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma A C. Clinical Cancer Research. 15 July 2020. DOI: 10.1158/1078-0432.CCR-19-3239.

Impacto: 12.531. Cuartil: Q1 (1er decil)

Fumanal M., Di Zeo D.E., Anguís V., Fernández-Diaz C., Alarcón F.J., Piñera R., Albaladejo-Riad N., Esteban M.A., Moriñigo M.A., Balebona M.C.. Inclusion of dietary Ulva ohnoi 5% modulates Solea senegalensis immune response during Photobacterium damselae subsp. piscicida infection. Fish and Shellfish Immunology. May 2020. DOI: 10.1016/j.fsi.2020.03.007.

Impacto: 4.581. Cuartil: Q1 (1er decil)

Abrisqueta P., Bosch F.. Venetoclax-obinutuzumab: harnessing complexity. Blood. March 2020. DOI: 10.1182/BLOOD.2019004463.

Impacto: 22.113. Cuartil: Q1 (1er decil)

Bosch F., Cantin G., Cortelezzi A., Knauf W., Tiab M., Turgut M., Zaritskey A., Merot J.L., Tausch E., Trunzer K., Robson S., Gresko E., Böttcher S., Foà R., Stilgenbauer S., Leblond V.. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. Leukemia. 1 February 2020. DOI: 10.1038/s41375-019-0554-1.

Impacto: 11.528. Cuartil: Q1 (1er decil)

Martorell L., Cortina V., Parra R., Barquinero J., Vidal F.. Variable readthrough responsiveness of nonsense mutations in hemophilia A. Haematologica. 31 January 2020. DOI: 10.3324/haematol.2018.212118.

Impacto: 9.941. Cuartil: Q1 (1er decil)

Tarrasó G., Real-Martinez A., Parés M., Romero-Cortadellas L., Puigros L., Moya L., Luna N., Brull A., Martín M.A., Arenas J., Lucia A., Andreu A.L., Barquinero J., Vissing J., Krag T.O., Pinós T.. Absence of p.R50X Pygm read-through in McArdle disease cellular models. DMM Disease Models and Mechanisms. 2020. DOI: 10.1242/dmm.043281.

Impacto: 5.758. Cuartil: Q1

Fox M.L., García-Cadenas I., Pérez A.M., Villacampa G., Piñana J.L., Ortí G., Montoro J., Roldán E., Bosch Vilaseca A., Martino R., Salamero O., Saavedra S., Hernandez-Boluda J.C., Esquirol A., Sierra J., Sanz J., Solano C., Bosch F., Barba P., Valcarcel D.. Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. Leukemia and Lymphoma. 2020. DOI: 10.1080/10428194.2020.1788015.

Impacto: 3.28. Cuartil: Q3

Bosch F., Dalla-Favera R.. Chronic lymphocytic leukaemia: from genetics to treatment. Nature Reviews Clinical Oncology. 1 November 2019. DOI: 10.1038/s41571-019-0239-8.

Impacto: 53.276. Cuartil: Q1 (1er decil)

Río P., Navarro S., Wang W., Sánchez-Domínguez R., Pujol R.M., Segovia J.C., Bogliolo M., Merino E., Wu N., Salgado R., Lamana M.L., Yañez R.M., Casado J.A., Giménez Y., Román-Rodríguez F.J., Álvarez L., Alberquilla O., Raimbault A., Guenechea G., Lozano M.L., Cerrato L., Hernando M., Gálvez E., Hladun R., Giralt I., Barquinero J., Galy A., García de Andoín N., López R., Catalá A., Schwartz J.D., Surrallés J., Soulier J., Schmidt M., Díaz de Heredia C., Sevilla J., Bueren J.A.. Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. Nature Medicine. 1 September 2019. DOI: 10.1038/s41591-019-0550-z.

Impacto: 36.13. Cuartil: Q1 (1er decil)

Scuoppo C., Wang J., Persaud M., Mittan S.K., Basso K., Pasqualucci L., Rabadan R., Inghirami G., Grandori C., Bosch F., Dalla-Favera R.. Repurposing dasatinib for diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 20 August 2019. DOI: 10.1073/pnas.1905239116.

Impacto: 9.412. Cuartil: Q1

Pardos-Gea J., Martínez F., Abrisqueta P., Santamaría A., Bosch F.. Acquired von Willebrand syndrome in a patient with small lymphocytic lymphoma and Sjögren's syndrome: Which associated condition should be prioritized?. Blood Coagulation and Fibrinolysis. 1 July 2019. DOI: 10.1097/MBC.0000000000000814.

Impacto: 1.203. Cuartil: Q4

Montoro J., Pomares H., Villacampa G., Merchán B., Molero A., Alonso E., Gallur L., Grau J., Salamero O., Roldán E., Saumell S., Ortega M., Sureda A., Bosch F., Arnan M., Valcárcel D.. Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes. Leukemia and Lymphoma. 12 May 2019. DOI: 10.1080/10428194.2018.1542151.

Impacto: 2.969. Cuartil: Q2

Ortí G., Iacoboni G., Barba P., Gimeno R., Roldán E., Fox L., Salamero O., Bosch F., Valcárcel D.. Donor lymphocyte infusion for BK virus hemorrhagic cystitis and nephropathy: a case report. Bone Marrow Transplantation. 1 May 2019. DOI: 10.1038/s41409-018-0402-3.

Impacto: 4.725. Cuartil: Q1

Younes A., Brody J., Carpio C., Lopez-Guillermo A., Ben-Yehuda D., Ferhanoglu B., Nagler A., Ozcan M., Avivi I., Bosch F., Caballero Barrigón M.D., Hellmann A., Kuss B., Ma D.D.F., Demirkan F., Yağci M., Horowitz N.A., Marlton P., Cordoba R., Wrobel T., Buglio D., Streit M., Hodkinson B.P., Schaffer M., Alvarez J., Ceulemans R., Balasubramanian S., de Jong J., Wang S.S., Fourneau N., Jurczak W.. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. The Lancet Haematology. February 2019. DOI: 10.1016/S2352-3026(18)30217-5.

Impacto: 10.406. Cuartil: Q1 (1er decil)

Pallarès Masmitjà M., Knödlseder N., Güell M.. CRISPR-gRNA Design. Methods in Molecular Biology. 2019. DOI: 10.1007/978-1-4939-9170-9_1.

Flinn I.W., Hillmen P., Montillo M., Nagy Z., Illés Á., Etienne G., Delgado J., Kuss B.J., Tam C.S., Gasztonyi Z., Offner F., Lunin S., Bosch F., Davids M.S., Lamanna N., Jaeger U., Ghia P., Cymbalista F., Portell C.A., Skarbnik A.P., Cashen A.F., Weaver D.T., Kelly V.M., Turnbull B., Stilgenbauer S.. The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 6 December 2018. DOI: 10.1182/blood-2018-05-850461.

Impacto: 16.562. Cuartil: Q1 (1er decil)

Bobillo S., Abrisqueta P., Sánchez-González B., Giné E., Romero S., Alcoceba M., González-Barca E., González de Villambrosía S., Sancho J.M., Gómez P., Bento L., Montoro J., Montes S., López A., Bosch F.. Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series. Annals of Hematology. 1 December 2018. DOI: 10.1007/s00277-018-3473-8.

Impacto: 2.85. Cuartil: Q3

Leblond V., Aktan M., Coll C.M.F., Dartigeas C., Kisro J., Montillo M., Raposo J., Merot J.L., Robson S., Gresko E., Bosch F., Stilgenbauer S., Foà R.. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb green study. Haematologica. 31 October 2018. DOI: 10.3324/haematol.2017.186387.

Impacto: 7.57. Cuartil: Q1 (1er decil)

Yeung C.C.S., Hockenbery D.M., Westerhoff M., Coutre S.E., Sedlak R.H., Dubowy R.L., Munugalavadla V., Taylor K., Bosch F.. Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis. Future Oncology. September 2018. DOI: 10.2217/fon-2017-0528.

Impacto: 2.279. Cuartil: Q3

Stilgenbauer S., Leblond V., Foà R., Böttcher S., Ilhan O., Knauf W., Mikuskova E., Renner C., Tausch E., Woszczyk D., Gresko E., Lundberg L., Moore T., Morris T., Robson S., Bosch F.. Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. Leukemia. 1 August 2018. DOI: 10.1038/s41375-018-0146-5.

Impacto: 9.944. Cuartil: Q1 (1er decil)

Montoro J., Gallur L., Merchán B., Molero A., Roldán E., Martínez-Valle F., Villacampa G., Navarrete M., Ortega M., Castellví J., Saumell S., Bobillo S., Bosch F., Valcárcel D.. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Annals of Hematology. 1 August 2018. DOI: 10.1007/s00277-018-3302-0.

Impacto: 2.85. Cuartil: Q3

Blaya D., Aguilar-Bravo B., Hao F., Casacuberta-Serra S., Coll M., Perea L., Vallverdú J., Graupera I., Pose E., Llovet L., Barquinero J., Cubero F.J., Caballería J., Ginès P., Sancho-Bru P.. Expression of microRNA-155 in inflammatory cells modulates liver injury. Hepatology. August 2018. DOI: 10.1002/hep.29833.

Impacto: 14.971. Cuartil: Q1 (1er decil)

Blanco G., Vardi A., Puiggros A., Gómez-Llonín A., Muro M., Rodríguez-Rivera M., Stalika E., Abella E., Gimeno E., López-Sánchez M., Senín A., Calvo X., Abrisqueta P., Bosch F., Ferrer A., Stamatopoulos K., Espinet B.. Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL. OncoImmunology. 3 June 2018. DOI: 10.1080/2162402X.2018.1432328.

Impacto: 5.333. Cuartil: Q1

Bosch F., Hallek M.. Venetoclax after idelalisib: Relevant progress for CLL. Blood. 12 April 2018. DOI: 10.1182/blood-2018-02-826396.

Impacto: 16.562. Cuartil: Q1 (1er decil)

González-Gascón y Marín I., Hernández-Sanchez M., Rodríguez-Vicente A.E., Puiggros A., Collado R., Luño E., González T., Ruiz-Xivillé N., Ortega M., Gimeno E., Muñoz C., Infante M.S., Delgado J., Vargas M.T., González M., Bosch F., Espinet B., Hernández-Rivas J.M., Hernández J.Á.. Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. Leukemia and Lymphoma. 4 March 2018. DOI: 10.1080/10428194.2017.1349901.

Impacto: 2.674. Cuartil: Q3

Gribben J.G., Bosch F., Cymbalista F., Geisler C.H., Ghia P., Hillmen P., Moreno C., Stilgenbauer S.. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. British Journal of Haematology. March 2018. DOI: 10.1111/bjh.15080.

Impacto: 5.206. Cuartil: Q1

Bobillo S., Abrisqueta P., Carpio C., Raheja P., Castellví J., Crespo M., Bosch F.. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement. Haematologica. 31 January 2018. DOI: 10.3324/haematol.2017.181636.

Impacto: 7.57. Cuartil: Q1 (1er decil)

Caminal M., Vélez R., Rabanal R.M., Vivas D., Batlle-Morera L., Aguirre M., Barquinero J., García J., Vives J.. A reproducible method for the isolation and expansion of ovine mesenchymal stromal cells from bone marrow for use in regenerative medicine preclinical studies. Journal of Tissue Engineering and Regenerative Medicine. December 2017. DOI: 10.1002/term.2254.

Impacto: 4.089. Cuartil: Q1

Carabia J., Carpio C., Abrisqueta P., Jiménez I., Purroy N., Calpe E., Palacio C., Bosch F., Crespo M.. Microenvironment regulates the expression of MIR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia. Scientific Reports. 1 December 2017. DOI: 10.1038/s41598-017-12135-7.

Impacto: 4.122. Cuartil: Q1

Dornier E., Rabas N., Mitchell L., Novo D., Dhayade S., Marco S., MacKay G., Sumpton D., Pallares M., Nixon C., Blyth K., MacPherson I.R., Rainero E., Norman J.C.. Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nature Communications. 1 December 2017. DOI: 10.1038/s41467-017-02101-2.

Impacto: 12.353. Cuartil: Q1 (1er decil)

Martorell L., Luce E., Vazquez J.L., Richaud-Patin Y., Jimenez-Delgado S., Corrales I., Borras N., Casacuberta-Serra S., Weber A., Parra R., Altisent C., Follenzi A., Dubart-Kupperschmitt A., Raya A., Vidal F., Barquinero J.. Advanced cell-based modeling of the royal disease: characterization of the mutated F9 mRNA. Journal of Thrombosis and Haemostasis. November 2017. DOI: 10.1111/jth.13808.

Impacto: 4.899. Cuartil: Q1

Fink A.M., Bahlo J., Robrecht S., Al-Sawaf O., Aldaoud A., Hebart H., Jentsch-Ullrich K., Dörfel S., Fischer K., Wendtner C.M., Nösslinger T., Ghia P., Bosch F., Kater A.P., Döhner H., Kneba M., Kreuzer K.A., Tausch E., Stilgenbauer S., Ritgen M., Böttcher S., Eichhorst B., Hallek M.. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. The Lancet Haematology. October 2017. DOI: 10.1016/S2352-3026(17)30171-0.

Impacto: 10.698. Cuartil: Q1 (1er decil)

Casacuberta-Serra S., Parés M., Golbano A., Coves E., Espejo C., Barquinero J.. Myeloid-derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes. Immunology and Cell Biology. 1 July 2017. DOI: 10.1038/icb.2017.4.

Impacto: 3.795. Cuartil: Q2

García-Marco J.A., Delgado J., Hernández-Rivas J.A., Ramírez Payer Á., Loscertales Pueyo J., Jarque I., Abrisqueta P., Giraldo P., Martínez R., Yáñez L., Terol M.J., González M., Bosch F.. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia. Medicina Clinica. 21 April 2017. DOI: 10.1016/j.medcli.2016.12.030.

Impacto: 1.168. Cuartil: Q3

Casós K., Ferrer-Curriu G., Soler-Ferrer P., Pérez M.L., Permanyer E., Blasco-Lucas A., Gracia-Baena J.M., Castro M.A., Sureda C., Barquinero J., Galiñanes M.. Response of the human myocardium to ischemic injury and preconditioning: The role of cardiac and comorbid conditions, medical treatment, and basal redox status. PLoS ONE. April 2017. DOI: 10.1371/journal.pone.0174588.

Impacto: 2.766. Cuartil: Q1

Orti G., Barba P., Fox L., Salamero O., Bosch F., Valcarcel D.. Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect. Experimental Hematology. 1 April 2017. DOI: 10.1016/j.exphem.2016.12.004.

Impacto: 2.436. Cuartil: Q3

Puiggros A., Collado R., Calasanz M.J., Ortega M., Ruiz-Xivillé N., Rivas-Delgado A., Luño E., González T., Navarro B., García-Malo M.D., Valiente A., Hernández J.á., Ardanaz M.T., Piñan M.á., Blanco M.L., Hernández-Sánchez M., Batlle-López A., Salgado R., Salido M., Ferrer A., Abrisqueta P., Gimeno E., Abella E., Ferrá C., Terol M.J., Ortuño F., Costa D., Moreno C., Carbonell F., Bosch F., Delgado J., Espinet B.. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions. Oncotarget. 2017. DOI: 10.18632/oncotarget.17350.

Purroy N., Carabia J., Abrisqueta P., Egia L., Aguiló M., Carpio C., Palacio C., Crespo M., Bosch F.. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. Oncotarget. 2017. DOI: 10.18632/oncotarget.13557.

Casacuberta-Serra S., Costa C., Eixarch H., Mansilla M.J., López-Estévez S., Martorell L., Parés M., Montalban X., Espejo C., Barquinero J.. Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis. Experimental Neurology. 1 December 2016. DOI: 10.1016/j.expneurol.2016.09.012.

Impacto: 4.706. Cuartil: Q1

Städler N., Shang A., Bosch F., Briggs A., Goede V., Berthier A., Renaudin C., Leblond V.. A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia. Advances in Therapy. 1 October 2016. DOI: 10.1007/s12325-016-0398-2.

Impacto: 2.709. Cuartil: Q2

Torres-Torronteras J., Cabrera-Pérez R., Barba I., Costa C., De Luna N., Andreu A.L., Barquinero J., Hirano M., Cámara Y., Martí R.. Long-Term Restoration of Thymidine Phosphorylase Function and Nucleoside Homeostasis Using Hematopoietic Gene Therapy in a Murine Model of Mitochondrial Neurogastrointestinal Encephalomyopathy. Human Gene Therapy. 1 September 2016. DOI: 10.1089/hum.2015.160.

Impacto: 4.187. Cuartil: Q1